ADME, DDI and adverse events of repurposed COVID-19 drugs
Table 2 summarizes the main metabolizing enzymes, DDI, and adverse events of repurposed COVID-19 drugs. COVID-drugs being a perpetrator: No clinically significant DDIs are anticipated except ritonavir and darunavir; COVID-drugs being a victim: Weak to moderate DDI risk is anticipated for COVID drugs that are mainly metabolized by CYP3A4 except ibrutinib.